Skip to content

Pfizer PFE Debt-to-assets

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Merck & Co. logo
Merck & Co.MRK
0.4×+0.1×
Amgen logo
AmgenAMGN
0.6×0.0×
Incyte logo
IncyteINCY
0.0×

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$147.73B+11.1%
Enterprise value$210.4B+9.2%
P/E12.2×
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Calculated from Pfizer’s reported figures.

Based on the most recent quarter.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's debt-to-assets?
Pfizer (PFE) reported debt-to-assets of 0.3× in Q1 2026.
How has Pfizer's debt-to-assets changed year-over-year?
Pfizer's debt-to-assets increased by 5.2% year-over-year, from 0.3× to 0.3×.
What is the long-term trend for Pfizer's debt-to-assets?
Over 4 years (2021 to 2025), Pfizer's debt-to-assets has grown at a 7.2% compound annual growth rate (CAGR), from 0.9× to 1.2×.
What does debt-to-assets mean?
What fraction of everything the company owns is funded by debt.
How do you interpret debt-to-assets?
A lower ratio indicates a more conservatively financed balance sheet. Rising debt-to-assets over time signals increasing financial risk.
How does debt-to-assets compare across companies?
Comparable within an industry; bounded between 0 and 1 for most non-financials, which makes cross-company reads cleaner than debt-to-equity.